MedTrace Logo

Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?

NCT00813514 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-11-21

No results posted yet for this study

Summary

Age related macular degeneration (AMD) is a multifactorial disease with a strong genetic component. Most importantly a genetic polymorphism in the gene encoding for the complement factor H (CFH) has been recently identified which is highly associated with an increased risk of developing AMD. This Tyr402His polymorphism located on chromosome 1q31 has been implicated to play a role in the development of the disease.

For this purpose a total of 200 patients with wet AMD will be included in the study. As described in detail below, the current study aims to identify potentially non-responders to anti-VEGF therapy based on genetic analysis of VEGF polymorphism and complement factor H polymorphism.

Conditions

  • Choroidal NeoVascularization
  • Age-Related Macular Degeneration

Interventions

GENETIC

VEGF genotyping

blood sample for gene analysis

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Leopold Schmetterer, Prof. Dr. · Department of Clinical Pharmacology

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00813514 on ClinicalTrials.gov